Anorgasmia in Men & the PSSD Overlap
Inability to Reach Orgasm - SSRI-Induced and Persistent Post-SSRI Forms
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved treatment; EMA acknowledged persistent post-SSRI dysfunction (2019)
Reference only. Not medical advice.
What can go wrong
Beyond the sexual symptoms, drug-induced and persistent forms carry substantial psychological burden and can complicate antidepressant adherence. The PSSD evidence base is weak (grade 2): prevalence unknown, mechanism unproven, and unvalidated 'treatments' are marketed online to a distressed population. The clinically responsible position is honest informed consent before SSRI use and avoiding both dismissal and overpromised cures.
This is something to take to a clinician. The Atlas can tell you what is known about anorgasmia in men & the pssd overlap in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Male anorgasmia is the persistent inability to reach orgasm despite adequate arousal and stimulation; it overlaps heavily with delayed ejaculation and is frequently iatrogenic. SSRIs and SNRIs are the leading cause, blunting or abolishing orgasm in a substantial minority of users. The contested extension is post-SSRI sexual dysfunction (PSSD), in which genital numbness, low libido, and anorgasmia persist after the antidepressant is stopped - a syndrome the European Medicines Agency formally acknowledged in 2019 by requiring label warnings, despite unknown prevalence, unproven mechanism, and no established treatment.
When orgasm won't come - and sometimes won't return after the pill stops.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Orgasm involves dopaminergic reward circuitry and the spinal ejaculatory reflex; high serotonergic tone (SSRIs/SNRIs) raises the orgasmic threshold and can abolish orgasm entirely. In PSSD, the proposed but unproven mechanisms include lasting downregulation of serotonin and dopamine signaling, epigenetic changes, persistent 5-HT receptor or transporter alterations, and reduced genital sensory function (some patients report penile/genital hypoesthesia), but none is established. The defining feature is that symptoms outlast drug clearance.
What people get wrong
Often saidSexual side effects always disappear once you stop the antidepressant
ActuallyFor most they do, but the EMA's 2019 action acknowledges a subset with persistent dysfunction (PSSD) after discontinuation; this is rare-to-unknown in frequency but real enough to warrant a label warning.
Often saidAnorgasmia just means low libido
ActuallyThey are different: a man can have intact desire and erection but be unable to climax. Anorgasmia must also be separated from anejaculation and retrograde ejaculation, which concern semen rather than the orgasm sensation.
Often saidPSSD is just relapsed depression
ActuallyPSSD is reported in people who took SSRIs for non-depression indications and whose mood is fine; the signature is sexual/genital and emotional-blunting symptoms persisting despite resolved or absent depression.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Drug-induced anorgasmia usually reverses on lowering, switching (e.g., to bupropion), or stopping the SSRI, and bupropion augmentation is sometimes tried. PSSD is the harder, contested entity: by definition it does not reverse on stopping, has no proven treatment, and overlaps with delayed ejaculation and post-finasteride syndrome in the broader 'persistent iatrogenic sexual dysfunction' debate. Anorgasmia should be distinguished from retrograde ejaculation and anejaculation, which are semen-delivery problems.
At a glance
- Leading drug cause
- SSRIs/SNRIs (orgasm blunting)
- Overlaps with
- Delayed ejaculation, low libido
- PSSD
- Symptoms persisting after stopping the drug
- EMA action
- 2019 label warning that dysfunction can persist
- Established treatment
- None
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Anorgasmia in Men & the PSSD Overlap. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Montejo et al., antidepressant sexual dysfunction prevalence2001
Prospective assessment found high rates (often cited 30-70%+) of sexual dysfunction including anorgasmia across SSRIs/SNRIs, frequently under-reported when not actively asked about
EMA PRAC review of persistent sexual dysfunction2019
Concluded sexual dysfunction may persist after SSRI/SNRI discontinuation; required label updates (PSSD acknowledgment)
Healy and colleagues / case-series literature on PSSD2010s-2020s
Characterized genital numbness, anorgasmia, and emotional blunting persisting after stopping; prevalence and mechanism remain unestablished